BA 015 gene therapy
Alternative Names: AMEP; BA-015 AMEP peptide; p-AMEP; Plasmid AMEP; SynfoldinLatest Information Update: 08 Sep 2023
At a glance
- Originator BioAlliance Pharma
- Developer BioAlliance Pharma; Valerio Therapeutics
- Class Antineoplastics; Gene therapies
- Mechanism of Action ADAM protein inhibitors; Angiogenesis inhibitors; Gene transference; Integrin alpha 5 beta 1 inhibitors; Integrin alphaVbeta3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Malignant melanoma; Solid tumours
Most Recent Events
- 09 Dec 2014 Discontinued - Phase-I/II for Malignant melanoma in France (IM)
- 09 Dec 2014 Discontinued - Phase-I/II for Malignant melanoma in Slovenia (IM)
- 01 Aug 2014 TopoTarget has merged with BioAlliance Pharma to form Onxeo SA